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Walking Ability of Stroke Patients: Efficacy of Tibial Nerve 
Blocking and a Polypropylene Ankle-Foot Orthosis
Heleen Beckerman, PhD, PT, Jules Becher, MD, Gustaaf J. Lankhorst, MD, PhD, 
André L. M. Verbeek. MD. PhD
* Î
ABSTRACT. Beckerman H, Becher J, Lankhorst GJ, Ver­
beek ALM. Walking ability of stroke patients: efficacy of tibial 
nerve blocking and a polypropylene ankle-foot orthosis. Arch 
Phys Med Rehabil 1996;77:1144-51.
Objective: To investigate the efficacy of tibial nerve blocking 
by percutaneous radiofrequency thermocoagulation and an 
ankle-foot orthosis on the walking ability of stroke patients with 
a spastic equinus or equinovarus foot.
Design: A placebo-controlled randomized clinical trial with 
a 2 X 2 factorial design and with a 3-month follow-up.
Setting: Outpatient clinic of a department of rehabilitation 
medicine.
Subjects: Sixty stroke patients (17 women, 43 men) with a 
median age of 58 years and a median period of 34 months 
poststroke were allocated to one of four treatment groups.
Main Outcome M easures: Changes in walking ability (mea­
sured with the Sickness Impact Profile category “ ambulation 
possible score range, 0% to 100%) and walking speed after 3 
months.
Results: With respect to walking ability, the efficacy of ther­
mocoagulation as compared with placebo thermocoagulation 
was .56% (95% confidence interval [Cl] —3.01% to 4.13%), 
whereas the efficacy of the ankle-foot orthosis as compared 
with the placebo ankle-foot orthosis was 2.72% (95% Cl —.94% 
to 6.38%). To study the potential synergistic effect of both 
treatments, a multivariate model was used; interaction between 
both treatments was small, .83% (95% Cl -6.73%  to 8.40%). 
Analysis restricted to the compilers (n = 30) showed an in­
creased efficacy of thermocoagulation and a decreased efficacy 
of the ankle-foot orthosis. The changes in comfortable and max­
imal safe walking speed were less than .lOm/sec and were nei­
ther clinically nor statistically significant (the median baseline 
values for the total group were .42m/sec and .56m/sec, respec­
tively).
Conclusion: No support was found for the beneficial effects 
of either thermocoagulation of the tibial nerve or a polypropyl­
ene ankle-foot orthosis in 5 degrees of dorsiflexion on the walk­
ing ability of stroke patients.
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ERCUTANEOUS radiofrequency thermocoagulation is a 
current treatment method in the management of intractable 
pain. Dorsal spinal roots (rhizotomy) as well as cranial nerves 
are blocked for control of chronic pain or trigeminal neuralgia. 
Percutaneous radiofrequency rhizotomy has also been shown to 
be an effective means of controlling generalized spasticity.1'6 
In 1987 the first clinical results were published on thermocoagu­
lation of peripheral nerves (obturator and tibial nerve).7 An 11- 
year-old cerebral palsied boy with spasticity of the femoral 
adductors and gastrocnemius muscles was treated successfully. 
Two uncontrolled studies followed: Arendzen8 in 1989 investi­
gated the effects of thermocoagulation of the tibial nerve in 14 
ambulatory stroke patients, and Herz et al6 in 1990 described 
the clinical results of sciatic nerve blocking in 32 nonambulatory 
patients. Percutaneous radiofrequency thermocoagulation of pe­
ripheral nerves is used for the relief of local spasticity as an 
alternative to chemical nerve blocks with phenol. It has been 
hypothesized that radiofrequency thermocoagulation would be 
more effective, especially in patients with severe spasticity. 
Furthermore, the duration of effects would be longer and the 
number of side effects (painful paresthesias) would be smaller, 
since no chemical agent is involved.
We present here the results of a placebo-controlled random­
ized clinical trial of the efficacy of thermocoagulation of the 
tibial nerve and an ankle-foot orthosis (AFO) on the walking 
ability of stroke patients with a spastic equinus or equinovarus 
foot. After the first 6 months of rehabilitation, approximately 
80% of stroke patients are able to walk independently, with or 
without using a walking aid.9,1” Nevertheless, many of these 
patients are still disabled with regard to mobility.11 This disabil­
ity is usually associated with a strong synergistic extension 
pattern in the lower limb, resulting in an equinus or equinovarus 
position of the foot during walking.1* In these patients, tibial 
nerve blocking by phenol or percutaneous radiofrequency ther­
mocoagulation is used to reduce spasticity of the calf muscles. 
A second option is to inhibit the spastic position of the foot 
using an ankle-foot orthosis (eg, a polypropylene AFO in a 5° 
dorsiflexion position). An AFO in a 5° dorsiflexion position also 
stimulates normal walking (ie, heel strike and foot unrolling).
Neither the efficacy of the separate treatments (ie, thermoco­
agulation of the tibial nerve and an AFO) nor the efficacy of 
the combined treatment on walking ability has previously been 
the subject of a randomized clinical trial. Although thermocoag­
ulation as well as ankle-foot orthoses improve gait parameters 
such as stride length, stance symmetry, and heel-contact time in 
hemiplegic patients,81-1,14 the question is whether they improve 
walking ability as measured with the Sickness Impact Profile 
category “ ambulation” , which is a self-assessment health status 
measure.15
PATIENTS AND METHODS
Study Design
A placebo-controlled randomized clinical trial with a 2 X  2 
factorial design was performed. The randomized clinical trial 
is generally considered to be the best design for intervention
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studies, with minimal threats to validity.1617 A factorial design 
is one in which two or more experimental treatments are studied 
simultaneously. The general features of a 2 X 2 factorial design 
are two treatment arms with two conditions of each treatment, 
resulting in 4 possible combinations.18 A factorial design offers 
the opportunity to investigate whether any combinations of 
treatments are particularly effective or notably ineffective.1618 
Randomization was carried out with sealed envelopes, prepared 
in advance by an independent statistician, using random per­
muted blocks.
Subjects
Stroke patients with walking problems caused by a spastic 
equinus or equinovarus position of the foot were eligible for 
the trial if they were between 18 and 75 years of age and had 
suffered a first ischemic or hemorrhagic stroke of a cerebral 
hemisphere resulting in hemiplegia. At least 4 months had to 
have elapsed between the cerebrovascular accident and partici­
pation to prevent confounding of the study results by initial 
recovery (the natural course).19 Sufficient communication and 
cognition abilities and a satisfactory general condition were 
required for full cooperation in the trial. To ensure blinding of 
the participants, patients treated previously by thermocoagula­
tion were excluded. Furthermore, a “ wash-out” period of at 
least 3 months was required if patients had been treated with 
phenol prior to participation. Patients were excluded if they met 
one or more of the following exclusion criteria: more than one 
stroke; brain stem infarction; unable to walk independently; 
neurologic, orthopedic, or vascular disorders negatively influ­
encing ambulatory activities. Exclusion criteria also included 
structural shortening of the soleus muscle and/or gastrocnemius 
muscle, skin lesions, or foot deformities, since they preclude 
the proper fitting of an AFO.
Before randomization, each patient received a nerve block 
with a local anesthetic (bupivacainechloride 0.5%), intended 
especially to diagnose those patients whose standing and walk­
ing ability was largely dependent on extensor spasticity. The 
diagnostic block only acts temporarily; the anesthetic effect 
fully disappears within 7 to 12 hours after the injection. In five 
patients this diagnostic nerve block had a temporary disabling 
effect on standing or walking; they were excluded from the 
trial. Sixty patients giving written informed consent were ran­
domized to one of four groups in accordance with the 2 X 2 
factorial design.
Thermocoagulation Arm
For thermocoagulation (TH) the tibial nerve was identified 
in the popliteal fossa, using transcutaneous stimulation. After 
anesthetizing the skin, a needle was placed into the tibial nerve. 
With low frequency stimulation, the nerve fibers innervating 
the spastic muscles that most hampered the patient’s gait (eg, 
soleus muscle, gastrocnemius muscle, tibial posterior muscle, 
or toe flexors) were further localized and anesthetized (5 cc 
lidocainechloride 2%). Subsequently, these fibers were heat- 
injured with radiofrequency energy (300kHz, Model RFG 3b 
Lesion Generator'1). The temperature was brought to 80°C within 
40 seconds and was held constant for the next 60 seconds. This 
procedure was repeated twice after a slight change of position 
of the needle within the nerve. This treatment protocol has 
already been proven clinically useful.8 The second treatment 
condition consisted of placebo thermocoagulation (PTH). The 
treatment protocol was similar, including the anesthetizing of 
the tibial nerve; however, radiofrequency energy output was
zero.
Ankle-Foot Orthosis (AFO)Arm
After the nerve blocking procedure, a polypropylene AFO 
was custom-made for each patient. The AFO under investigation 
consisted of a polypropylene AFO in 5° dorsiflexion, corrected 
for shoe heel height. This AFO has been designed to prevent 
an equinus or equinovarus position of the foot during walking 
and inhibit the synergistic extension pattern.20 During the stance 
phase only a minimal dorsiflexion is possible, caused by the 
transformation of the material. On the contrary, plantar flexion
is impossible. The placebo AFO (PAFO) consists of a polypro-
i
pylene hinged AFO that allows normal range of motion of 
dorsiflexion and plantar flexion. Varus and valgus positioning 
of the foot is corrected by both AFOs.
Outcome Measures
»
In this trial, walking ability was used as primary outcome 
measure. Walking means “progressing on foot” , whereas abil­
ity means “ to perform an activity in the manner or within the 
range considered normal for a human being.” 21 Actual walking 
ability was measured with the Sickness Impact Profile (SIP), 
a self-assessment measure of health-related dysfunctions, which 
has been validated for the Dutch language.22,21 The SIP covers 
12 different categories of disabilities, using 136 yes/no state­
ments, and gives a weighted score to each statement (see appen­
dix). Furthermore, a physical dimension score (based on 3 cate­
gories) and a psychosocial dimension score (based on 4 
categories) can be calculated. The scale values (weights) for 
each item answered affirmatively are added. The sum is divided 
by the maximum possible dysfunction score for that category, 
multiplied by 100. Potential scores range from 0% to 100%, 
with higher percentages representing greater ‘ ‘sickness impact’ ’ 
and, thus, poorer health.15 We used the category “ ambulation” 
(12 items), or more specifically the change from baseline score, 
as the primary outcome measure (see appendix).
A secondary outcome measure concerns walking speed. The 
patients walked on an 11 -m walkway at a comfortable and safe 
maximum speed while wearing, respectively, shoes, orthosis, 
and walking device. Patients were instructed to walk to the 
other side of the . human movement laboratory at their normal 
speed and as fast as judged safely by themselves. The velocity 
was automatically measured with two infrared beams over a 
distance of 5.5m. In addition, muscle function impairments, 
including the motor function of the lower extremity, sitting 
and standing balance, spasticity, ankle clonus, muscle tone, and 
Achilles tendon reflex,24 as well as satisfaction, compliance, 
and side effects were assessed by clinical examination or by 
questionnaire.
All measurements took place at baseline and 12 weeks after 
fitting the orthosis.
15
Blinding
The patients were treated by one physiatrist and an orthotist. 
The physiatrist was unblinded, whereas the orthotist was only 
blinded to the nerve blocking part of the trial; neither was 
involved with the measurements. Baseline measurements and 
follow-up measurements were conducted by two evaluators who 
were also blinded to the nerve block. The patients were blinded 
or at least naive to both the peripheral nerve block as well as 
the AFO. Success of patient blinding was checked by asking 
patients at the final follow-up which treatments they thought 
they had received.
Statistical Analyses
The efficacy of thermocoagulation and the AFO was exam­
ined both without and with statistical controls for confounding
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variables. First, lor walking ability and walking speed the 
groups were compared on their median change scores at 3- 
month follow-up. The proper use of randomization only guaran­
tees that there is no bias in the selection of patients for the 
different treatment groups. However, it provides no guarantee 
for baseline similarity of the treatment groups. Therefore, multi­
ple linear regression analyses were additionally used to estimate 
group differences adjusted for differences at the baseline for 
important prognostic factors, and to enlarge the precision of 
the point estimates of the treatment effects (ie, smaller 95% 
confidence intervals of the regression coefficients). The term 
“ treatment effects”  is used to indicate the adjusted differences 
in change scores between groups with respect to walking ability 
and walking speed, respectively, to estimate the efficacy of 
thermocoagulation and the AFO. Age, time since stroke, hemi- 
neglect, thalamic (pain) syndrome, ankle clonus, postural reflex 
activity, quadriceps strength, and paramedical cointerventions 
were a priori defined as prognostically important. Nevertheless, 
making allowance for our sample size and to prevent so-called 
“ overfitting” of the data, the regression model was limited to 
the three prognostic factors with the highest p values.25,26 These 
three factors were selected with backward regression analysis. 
The analyses were carried out with SPSS-PC+ version 4.01.b
To measure the impact of the compliance of the (P)AFO on 
the study results, we also performed a “complier analysis.” This 
analysis was restricted to patients who stated that they had worn 
the orthosis every day or nearly every day. This was verified by 
the clinician’s report at the follow-up visits. Immediately after the
procedure, the technical performance of the thermocoagulation in 
a few patients was qualified as “ probably not perfect.” These 
patients were also excluded from the “ complier analysis.
RESULTS 
Study Population
Between August 1992 and May 1994, 60 stroke patients were 
enrolled in the trial. Seventeen women and 43 men with a 
median age of 58 years (range, 21 to 72 years) and with a 
median time since stroke of 34 months (range, 5 to 185 months) 
were randomly allocated to one of four treatment groups: group
1, TH/AFO; group 2, PTH/AFO; group 3, TH/P AFO; group 4, 
PTH/PAFO. Table 1 shows the extent of baseline similarity 
of the four groups with respect to demographic and clinical 
characteristics. There were some essential differences between 
the four groups at baseline. Group 4, the double-placebo group, 
had the highest median age (60.5 years) and the shortest median 
period poststroke (2 years), and more left-sided than right-sided 
hemiplegic subjects, but at baseline also had poorer scores on 
the outcome measures (table 2).
Three patients withdrew from the trial. Reasons for with­
drawal were unknown in 2 cases (both group 2), whereas one 
patient (group 4) was disappointed with the treatment results 
and refused further cooperation.
Walking Ability
Table 3 shows the crude (ie, not adjusted for baseline differ­
ences) median improvement on the main outcome measures for
Table 1: Baseline Characteristics of the Participants
Characteristic
Group 1: TH/AFO 
(n - 15)
Group 2: PTH/AFO
<n - 16)
Group 3: TH/P AFO 
in = 15)
Group 4: PTH/PAFO 
{n = 14)
Total Study Population
(n - 60)
Gender
Female 3 3 7 4 17
Male 12 13 8 10 43
Age (yr)
Median 58 55.5 58 60.5 58
Range 21-71 33-69 26-66 41-72 21-72
Months poststroke
Median 34 39.5 47 24.5 34
Range 5-64 5-143 12-154 9-185 5-185
Hemiplegic side
Left 7 7 4 8 26
Right 8 9 11 6 34
Type of stroke
Hemorrhagic 6 4 3 2 15
Ischemic 9 12 12 12 45
Ankle clonus
< 5 beats 6 3 6 6 21
^ 5 beats 9 13 9 8 39
Postural reflex activity
Yes 13 13 14 10 50
No 2 3 1 4 10
Quadriceps strength
Decreased 8 4 7 11 30
Normal 7 12 8 3 30
Hemineglect
Probably 4 2 1 4 11
Probably not 11 14 14 10 49
Thalamic syndrome
Yes 3 2 1 2 8
No 12 14 14 12 52
Paramedical cointerventions
1 11 9 10 11 41
No 4 7 5 3 19
Comorbidity
E5 1 13 11 7 10 41
No 2 4 8 4 19
Spasmolytics
Yes 2 0 4 2 8
No 13 16 11 12 52
Abbreviations: TH, thermocoagulation; PTH, placebo thermocoagulation; AFO, ankle-foot orthosis; PAFO, placebo ankle-foot orthosis.
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Table 2: Baseline Values of Main Outcome Measures
Characteristic
Sickness Impact Profile (%} 
Ambulation
Group 1: 
TH/AFO 
(n - 15)
Group 2: 
PTH/AFO
{n - 16)
Group 3: 
TH/PAFO
in = 15)
Group 4: 
PTH/PAFO
(n = 14)
Median 44.5 43.3 48.1 50.4Range 10.7-58.2 29.8-67.2 12.5-72.5 27.9-63.2Physical dimension
Median 31.9 26.5 27.7 39.9Range 4.3-60.7 7.6-45.4 8.0-53.8 18.3-62.8Total score
Median 28.6 23.1 25.1 35.0
Range 6.5-50.7 8.2-47.5 11.2-45.3 11.7-53.3
Walking speed (m/sec)
Comfortable with shoes
Median .45 . 44 .42 .32
Range ,17-1.39 .19-.85 ,08-1.15 .17-1.09
Maximal safe with shoes
Median .61 .55 .59 .40
Range .25-1.64 .33-1,13 .19-1.46 .17-1.48
Abbreviations: As in table 1.
each group separately. For each patient, all follow-up measure­
ments took place 12 weeks after fitting the orthosis, that is, 14 
weeks after the nerve blocking procedure. Groups 1 and 2, 
unlike groups 3 and 4, showed a small improvement on all 
outcome measures.
The magnitude of the adjusted group differences, represent­
ing the treatment effects, and the 95 % confidence intervals (Cl), 
are presented in table 4. These estimates are adjusted for differ­
ences between the groups at baseline with respect to age (years), 
period poststroke (months), and quadriceps strength (normal/ 
decreased). This linear regression model explained 17% of the 
variation in change scores of walking ability. The small change 
in “ sickness impact” on ambulation casts doubt on the clinical 
significance of the efficacy of both thermocoagulation and the 
AFO. Figure 1 presents the cumulative distributions of the pro­
portion of improved patients per treatment group. On the ab­
scissa, scores of more than 0 indicate an improvement of the
Table 3: Median Improvement on Main Outcome Measures Per
Treatment Group at 12-Week Follow-Up
Outcome Measures N Median Range
Improvement SIP ambulation (%)
1. Thermo/AFO 15 6.45 “ 4.7/15.0
2. Placebo thermo/AFO 14 3.23 -12.8/13.2
3. Thermo/placebo AFO 15 —2,65 -9.4/21.7
4, Placebo thermo/placebo AFO 13 .00 -9.0/15.8
Improvement SIP physical dimension (%)
1. Thermo/AFO 15 3.15 -6.6/12.5
2. Placebo thermo/AFO 14 3.05 -1.5/10.0
3. Thermo/placebo AFO 15 .72 — 11.4/10.0
4, Placebo thermo/placebo AFO 13 .84 - 11.2/8.6
Improvement SIP total score (%)
1. Thermo/AFO 15 .79 -5.5/17.0
2. Placebo thermo/AFO 14 2.52 -1.9/10.2
3. Thermo/placebo AFO 15 — 1.47 -10.1/9.5
4. Placebo thermo/placebo AFO 13 1.02 -9.9/8.1
Walking speed (m/sec) 
Comfortable with shoes
1. Thermo/AFO 15 .01 - .09/.20
2. Placebo thermo/AFO 14 .05 -.15/.17
3. Thermo/placebo AFO 15 -.01 -.34/. 11
4. Placebo thermo/placebo AFO 13 -.01 -.07/. 19
Maximal safe, with shoes
1. Thermo/AFO 14 .02 —.16/.18
2. Placebo thermo/AFO 13 .04 -.33/. 18
3. Thermo/placebo AFO 13 -.02 -.48/. 15^  ^  t a  V
4. Placebo thermo/placebo AFO 13 .02 —.21/.87
Positive signs indicate improvement from the baseline; negative signs 
indicate a decline from the baseline scores.
Abbreviations: thermo, thermocoagulation; placebo thermo, placebo 
thermocoagulation; AFO, ankle-foot orthosis.
Table 4: Adjusted Treatment Effects With 95% Confidence Intervals for
the Main Outcome Measures at 12-Week Follow-Up
■
Outcome Measure
Adjusted
Difference
(Effect)
95% Confidence 
Interval
Improvement SIP ambulation (%)
E f f e c t T H |AF 0  (group 1-2) .99 -4.15/6.13
EffecttHip a f o  (9roup 3-4) .16 -5.10/5.41
EffectAfoiTH (group 1-3) 3.10 -1.92/8.11
EffectAF01 p t h  (group 2 - 4 ) 2.26 -3.36/7.89
Interaction .83 -6.73/8.40
Improvement SIP physical dimension (%)
E f f e c t j H i A F o  (group 1-2) -.63 -4.38/3.13
Effect™ipafo (group 3-4) -1.09 -4.92/2.75
EffectAFoiTH (group 1-3) 1.26 -2.40/4.92
E f f e c t A p o i p t h  (group 2-4) .80 -3.30/4.91
Interaction .46 -5.06/5.98
Improvement SIP total score (%)
EffectiHiAFo (group 1-2) -1.37 -5.14/2.40
EffectTHipafo (group 3-4) -1.59 -1.59/2.26
EffectAFoiTH (group 1-3) 2.49 -1.19/6.16
EffectAF0|pTH (group 2-4) 2.27 -1.85/6.39
Interaction .22 - 5.33/5.76
Walking speed (m/sec) 
Comfortable with shoes
EffectiHiAFo (group 1-2) -.02 —.08/.04
Effect™|pafo (group 3-4) -.02 —.09/.04
EffectAFoiTH (group 1-3) .01 —.05/.07
EffectAF0|pth (group 2-4) .01 —.06/.07
Interaction .01 -.08/. 10
Maximal safe, with shoes
EffectiHiAFo (group 1-2) -.04 —. 11/.04
EffectTHi p a f o  (group 3-4) -.00 —-08/.08
E f fe c tAFoiTH (group 1-3) .03 —.05/. 10
EffectAFoi p t h  (group 2-4) .06 —.02/. 15
Interaction -.04 -.15/. 07
Effects adjusted for baseline differences with respect to age, period 
poststroke, and quadriceps strength. Positive signs indicate improvement 
from the baseline; negative signs indicate a decline from the baseline 
scores. EffectTH|AFo is the mathematical notation, expressing the effect of 
thermocoagulation (as compared with placebo thermocoagulation) under 
the condition of wearing the AFO.
Abbreviations: As in table 1.
walking ability as measured with the SIP. If one chooses a score 
on the abscissa, one can read on the ordinate the proportion of 
patients of the four treatment groups with at least that score. 
The curves of groups 1 and 2 (both with the AFO) are almost 
identical, and are favorable (higher) as compared with the 
curves of groups 3 and 4 (both with the PAFO), respectively.
% patients 
1 0 0 * ^
80 -
60 -
40 -
20 -
0
change score (%) SIP ambulation
Fig 1. Improvement of walking ability: cumulative of distributions of the 
proportion of improved patients per treatment group (♦, TH/AFO; +, 
PTH/AFO; *, TH/PAFO; ■, PTH/PAFO).
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In groups l and 2 nearly all patients improve, whereas in the 
other two groups less than half of the patients improve.
The results on walking speed (in meters per second) are not 
completely consistent with the results on SIP ambulation (table 
4). (Pearson’s correlation coefficient between change in SIP 
score and change in comfortable walking speed r = .20 with 
one-tailed p = .07). Nevertheless, they lead to a similar conclu­
sion. A small and clinically irrelevant improvement of comfort­
able walking speed as well as maximal safe walking speed 
could only be demonstrated in the ankle-foot orthosis group as 
compared with the placebo orthosis group.
Compiler Analysis
Twenty-eight patients did not achieve optimal compliance 
with respect to the (placebo) AFO. In two additional cases the 
thermocoagulation was not perfect from a technical point of 
view. A compiler analysis was done on the patients who com­
plied well (n = 30; group sizes: 6, 13, 5, and 6, respectively). 
Table 5 presents the results of the complier analysis together 
with the results of the full analysis, using the same linear regres­
sion model. In this table, the results are averaged for each 
treatment irrespective of the second treatment (ie, the small 
interaction effects are ignored). With respect to walking ability 
(SIP ambulation), the efficacy of thermocoagulation increases 
in the complier population: 4.28% as compared to .56% in the 
full study population. On the other hand, the efficacy of the 
ankle-foot orthosis decreases (—1.69% for the compliers and 
2.72% in the total group). With respect to walking speed, the 
differences between the compliers and the full analysis are 
small, with a maximum of .06m/sec.
Adverse Effects
Twenty patients had at least one complaint about the active 
(n = 11) or inactive thermocoagulation (/i = 9), whereas 44 
patients had one or more complaints about their custom-made 
AFO (n = 21) or PAFO (n = 23). Efforts were made to solve 
each problem as soon as possible.
With respect to the nerve block three categories of complaints 
could be distinguished: (1) local problems caused by the injec­
tion itself (n = 4); (2) neurological problems or problems related 
to the autonomic nervous system; the most severe problems 
were reflex sympathetic dystrophy (n = 1) and extended neural­
gia (1 treated with TH, and 1 treated with PTH). Other minor
Table 5: Adjusted Treatment Effects: Comparison of Complier Analysis
(n = 30) With Full Analysis (n = 57)
Outcome Measure
Adjusted
Effect
Total
Group 95% CÏ
Adjusted
Effect
Compliers 95% C!
Improvement SIP 
ambulation (%)
EffeCtth«rmoconoul«tlon .56 “ 3.01/4.13 4.28 -.04/8.59
EffectApo 2.72 -.94/6.38 — 1.69 -6.54/3.17
Walking speed 
(m/sec)
Comfortable with 
shoes
Effectthormocon0ulotlon — .02 -.06/.02 .00 -.07/. 07
EffectApo .01 -,03/. 06 .02 — .05/. 10
Maxima) safe, with 
shoes
EffeCtthQcmocongulniloii — .02 -.07/. 03 .02 -.06/. 11
EffectAj:o .04 -.01A10 .10 .02/. 19
Effects adjusted for baseline differences with respect to age, period 
poststroke, and quadriceps strength. Positive signs indicate improvement 
from the baseline; negative signs indicate a decline from the baseline 
scores.
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Fig 2. Percentage of patients with local, neurological, and/or biomechan 
ical complaints from thermocoagulation (S ) or placebo thermocoagula 
tion
complaints were temporary burning sensations of the foot and 
muscle fibrillations, especially at night; (3) problems related to 
biomechanical changes, such as a stiff knee or leg, muscle pain 
or muscle cramp, instability of the ankle, and dropping of the 
foot during walking (fig 2). Both neurological as well as biome­
chanical problems were more prevalent in the thermocoagula­
tion group (23.3% of the patients). However, 13.3% and 16.7% 
of the placebo-treated patients also had neurological or biome­
chanical complaints, respectively, thought to be associated with 
placebo thermocoagulation.
With respect to the orthoses, problems were related to (1) 
range of motion (ROM) of the (P)AFO. In case of the active 
AFO, the foot is forced in 5° dorsifiexion. This results in a 
continuous stretching of the calf muscles, which was sometimes 
experienced as unpleasant. Furthermore, it results in a knee 
flexion during gait (stance-phase) and standing. With respect to 
the PAFO there is a free range of motion. The patient is stimu­
lated to actively dorsiflex his foot or raise his knee; otherwise 
he will stumble over his foot or experience other problems during 
walking. (2) Walking. (3) Shoes: although the polypropylene 
(P)AFO is only a few millimeters thick, nearly a quarter of the 
patients complained about wounds on the toes, toe clawing, or 
burning feelings of the foot. New shoes with a broad instep, and 
mostly one size larger than normal, solved this problem. (4) 
Fitting of the (P)AFO: both orthoses caused a number of prob­
lems concerning the fitting of the orthosis (32.2% in the AFO 
group and 30% in the PAFO group). (5) Handling of the (P)AFO 
and/or the material: sweaty foot and calf, metal allergy, and 
problems caused by the instep fixation bandage. Some patients 
were no longer able to put on their shoe and (P)AFO unaided 
(fig 3). Problems related to walking, the shoes, and the material 
were slightly more common among the PAFO group, whereas 
problems related to ROM were more common in the AFO group.
DISCUSSION
To our knowledge, this was the first randomized clinical trial 
of the effects of thermocoagulation and a polypropylene AFO 
on the walking ability of stroke patients. Even for phenolizadon 
of the tibial nerve, a well-known nerve blocking procedure with 
the same therapeutic intention, no randomized clinical trials 
have been conducted until now.27 Our clinical trial shows that 
the efficacy of both therapeutic interventions appeai-s to be nei­
ther statistically significant nor clinically relevant, despite the 
thermocoagulation performed by a highly skilled physiatrist and 
the AFO fitted by an experienced orthotist.
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Table 6: Blinding ProcedureThe high noncompliance (50%), even in the group with two 
active treatments, was already an indicator of the disappointing 
results after 3 months. The objective results, however, accord 
with the lack of satisfaction of the patients with the treatment 
results. Only 17% of the patients were satisfied, 38% were 
dissatisfied, with 42% being neither. At the end of the follow- 
up period, each patient was also asked to guess which treatments 
he/she had received, and to indicate his/her degree of certainty 
about these guesses on a seven-point scale (table 6). In the 
active thermocoagulation groups, the number of incorrect 
guesses exceeded the number of correct ones, whereas the oppo­
site held for the placebo thermocoagulation groups. In our opin­
ion these results also express the patients’ disappointment about 
the results of the active thermocoagulation, rather than any un­
masking of the placebo thermocoagulation. The higher mean 
certainty scores of the incorrect guesses support this argument.
Concerning the ankle-foot orthosis, the percentage of correct
guesses in the total AFO group was rather high. In the PAFO with their spasticity removed, would achieve a better fit for 
group the percentages of correct and incorrect guesses were their orthoses. This could not be confirmed by our compliance
Correct
Guess
Certainty
Score
Incorrect
Guess
Certainty
Score
Blinding
thermocoagulation
TH groups 10 (35.7%) 3.50 18 (64.3%) 3.67
PTH groups 17 (60.7%) 2.88 11 (39.3%) 3.09
Blinding ankle-foot
orthosis
AFO groups 21 (72.4%) 2.90 8 (27.6%) 2.50
PAFO groups 15 (51.7%) 4.27 14 (48.3%) 4.00
For thermocoagulation, patients were asked, "Which nerve block do you 
think you received, the real nerve block or the placebo?'' For ankle-foot 
orthosis, "Which AFO do you think you received, the real one or the 
placebo?" Mean certainty score presented (0 = absolutely unsure about 
the answer; 6 = absolutely sure about the answer).
Abbreviations: As in table 1.
nearly equal. The patients with a PAFO were the most certain 
about their correct choice.
data and also was not observed by the orthotist. Noncompliers 
mostly used their old orthoses again. This means that in the full
Compliance to the assigned treatment is of particular impor- analysis the contrast between the groups was biased by the old
tance. A “ pragmatic”  analysis of the total study population, 
disregarding noncompliance, may result in an underestimation
orthoses, whereas in the complier analysis the original experi­
mental contrast persisted (AFO vs PAFO). Furthermore, as both
of the true treatment effects. With an “ explanatory” approach experimental orthoses limit varus and valgus positioning of the
confined to compliance data only, one hopes to come nearer to foot, the positive effects seen in the full analysis and not in the
the truth, which is an estimation of the efficacy of a treatment complier analysis could be due to this stabilizing function.
under optimal circumstances, including fully compliant patients. 
On the other hand, with the advantages and disadvantages of a 
treatment, and taking the degree of patient compliance into
account, the “ pragmatic”  approach provides an estimation of 
the effects that are best related to actual clinical practice,16 
because patient populations in clinical practice consist of a mix 
of more or less compliant patients.
It is difficult to explain the differences found between both 
analyses with respect to walking ability. A potential problem 
of a factorial design is that noncompliance over one therapeutic 
contrast, given that the efficacy of that intervention depends 
on compliance, also affects a valid comparison of the other 
therapeutic contrast and vice versa.28 The increased efficacy of 
thermocoagulation, irrespective of the AFO used, is hard to
Using a factorial design has specific implications for group 
sizes. The sample size calculation was initially based on the 
assumption that a reduction of one item or 8% of the SEP “ am­
bulation’ ’ score, taking the baseline value into account, would 
constitute a clinically important difference between the groups. 
When the focus is on the two separate main effects of the 
treatments, nine patients per group, that is, 36 patients in total, 
were needed to obtain a study power of 90% (5% significance; 
one-sided test). However, demonstrating a significant interac­
tion effect between thermocoagulation and the AFO with the 
same power would require four times the total sample size.29 
Therefore, with our sample size there is an increased risk of a 
false negative interaction effect.
In chronically disabled people, therapeutic effects tend to be
explain. Compliance could have been induced by the good re- modest, especially when they are measured in behavioral terms,
suits of thermocoagulation. However, patients receiving placebo using health status instruments. Nevertheless, as health status
thermocoagulation were more compliant. With respect to the instruments such as the SIP are increasingly used, information 
(P)AFO, one might expect that the thermocoagulated patients,
%  patients
35
30
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20
15 -
10
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0
ROM walking shoes fitting
is needed about the translation of unit changes in health status 
measures into clinically meaningful terms.30 Until now, there 
have been no standardized methods for defining the magnitude 
of minimal clinically important changes.31 Therefore, in most 
cases, arbitrary choices are made, as were made by us. Although 
the association between changes in functional status and 
changes in physiological parameters is far from clear, some 
kind of calibration would be helpful to translate the clinical 
implications of changes in health status scores.12
With respect to walking speed there is more information 
available. Normal walking speed varies between 1.39m/sec in 
men between the ages of 20 and 89 years33 and 1.29m/sec in 
women (20 to 70 years).34 Healthy men beyond the age of 60 
still have a walking speed of 1.18m/sec and are able to increase 
their speed to at least 1.60m/sec.33 Normal walking speed in 
healthy women 64 years of age and older is .96m/sec (SD .23m/ 
sec).35 These elderly women were able to increase their speed 
to 1.42m/sec (SD .30m/sec). To function independently within 
aterial the community, stroke patients must walk at velocities much
Fig 3. Percentage of patients with adverse effects of the ankle-foot or­
thosis (E3) or placebo ankle-foot orthosis (ED) related to the range of 
motion, walking, shoes, fitting, and/or handling and material.
greater than measured in our study. The median comfortable 
and maximal safe walking speeds of our study population at 
baseline were .42m/sec and .56m/sec, respectively, whereas the
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adjusted changes were less than .10m/sec (EffectAW) for the 
compliers). To cross the street safely a velocity of .74m/sec in 
rural towns, .98m/sec in small towns, and 1.06m/sec in cities 
seems minimally necessary in the USA.16 The Swedish norm 
of 1.4m/sec necessary to negotiate traffic-light-controlled inter­
sections safely is even higher,17 and even most of the healthy 
population should increase their normal walking speed.
To find a sufficient number of patients we used many sources 
of patient recruitment. Altogether, this resulted in a severely 
and chronically disabled study population. We were impressed 
by the enormous problems these chronic stroke patients encoun­
ter daily. A 5-year follow-up study showed that functional capa­
bilities after stroke, including walking, are not stable, but de­
cline further.115 The search for effective treatment possibilities to 
improve walking abilities, therefore, remains urgent. Moreover, 
because the reduction of spasticity and use of an orthosis (and 
try-outs) are seen as especially important during early rehabilita­
tion a few weeks after the cerebrovascular accident, it still re­
mains interesting to investigate the potential benefits of thermo­
coagulation combined with the polypropylene ankle-foot 
orthosis during early rehabilitation. Although noncompliance in 
the placebo AFO groups was higher than in the AFO groups, 
both orthoses caused problems. From a pragmatic point of view, 
there is much room left for further improvement of the AFO. 
The fitting of a polypropylene AFO is an accurate and time- 
consuming process and demands much attention from both the 
orthotist and the physiatrist. Our findings underline the impor­
tance of continued careful monitoring of the suitability of the 
AFO at regular intervals in order to guarantee an optimal fitting.
The question may be raised if the lack of effect is an inevita­
ble result of a heterogeneous stroke population. However, they 
formed a homogeneous group with regard their spastic equinus 
position of the foot. The design of the trial was such that if the 
experimental treatments had any pronounced effect on walking 
ability, we would have been able to detect this effect. Moreover, 
the diagnostic nerve block and subsequent exclusion from the 
trial of patients whose walking ability declined afterwards in­
sured that only those expected to improve were randomized. 
So, a priori we tried to select a homogeneous group of patients 
with spastic foot problems who were likely to respond to the 
experimental therapy. In conclusion, the lack of effect of this 
study is not the result of studying this heterogeneous group of 
stroke patients; rather, it is simply because both thermocoagula­
tion and the ankle-foot orthosis lack a pronounced effect on the 
walking ability of stroke patients.
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APPENDIX: SICKNESS IMPACT PROFILE, 
CATEGORY “AMBULATION”
1. I get around in a wheelchair (96)
2. I do not walk at all (105)
3. I do not walk up or down hills (56)
4. I walk only with help from someone (88)
5. I get around only by using a walker, crutches, cane, walls, 
or furniture (79)
6. I walk shorter distances or stop to rest often (48)
7. I do not use stairs at all (83)
8. I use stairs only with mechanical support, for example, 
handrail, cane, crutches (67)
9. I walk up or down stairs only with assistance from someone 
else (76)
10. I walk by myself but with some difficulty, for example 
limp, wobble, stumble, have a stiff leg (55)
11. I go up and down stairs more slowly, for example, one step 
at a time, stop often (54)
12. I walk more slowly (35)
(842 points 100%)
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